22 Jul Cellusion
Shin Hatou, M.D., Ph.D., CEO
Cellusion is a regenerative medicine startup founded by three professors in Keio University’s School of Medicine, Department of Ophthalmology in Japan. Cellusion has several unique technologies including a highly efficient direct differentiation induction method to produce corneal endothelial substituted cells from iPS cells. The company’s lead program, CLS001 targeting Bullous Keratopathy, starts a first-in-human clinical study at Keio University Hospital soon. Additionally, the company has several pipelines focusing on not only ophthalmologic diseases, but also beyond.